Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 269

1.

Prime Minister for a day: children's views on junk food marketing and what to do about it.

Signal LN, Jenkin GL, Barr MB, Smith M, Chambers TJ, Hoek J, Mhurchu CN.

N Z Med J. 2019 Mar 29;132(1492):36-45.

PMID:
30921310
2.

Children's everyday exposure to food marketing: an objective analysis using wearable cameras.

Signal LN, Stanley J, Smith M, Barr MB, Chambers TJ, Zhou J, Duane A, Gurrin C, Smeaton AF, McKerchar C, Pearson AL, Hoek J, Jenkin GLS, Ni Mhurchu C.

Int J Behav Nutr Phys Act. 2017 Oct 8;14(1):137. doi: 10.1186/s12966-017-0570-3.

3.

Kids'Cam: An Objective Methodology to Study the World in Which Children Live.

Signal LN, Smith MB, Barr M, Stanley J, Chambers TJ, Zhou J, Duane A, Jenkin GLS, Pearson AL, Gurrin C, Smeaton AF, Hoek J, Ni Mhurchu C.

Am J Prev Med. 2017 Sep;53(3):e89-e95. doi: 10.1016/j.amepre.2017.02.016. Epub 2017 Apr 25.

PMID:
28455122
4.

Animal models of maternal high fat diet exposure and effects on metabolism in offspring: a meta-regression analysis.

Ribaroff GA, Wastnedge E, Drake AJ, Sharpe RM, Chambers TJG.

Obes Rev. 2017 Jun;18(6):673-686. doi: 10.1111/obr.12524. Epub 2017 Mar 30. Review.

5.

High-fat diet disrupts metabolism in two generations of rats in a parent-of-origin specific manner.

Chambers TJG, Morgan MD, Heger AH, Sharpe RM, Drake AJ.

Sci Rep. 2016 Aug 23;6:31857. doi: 10.1038/srep31857.

6.

Analgesic exposure in pregnant rats affects fetal germ cell development with inter-generational reproductive consequences.

Dean A, van den Driesche S, Wang Y, McKinnell C, Macpherson S, Eddie SL, Kinnell H, Hurtado-Gonzalez P, Chambers TJ, Stevenson K, Wolfinger E, Hrabalkova L, Calarrao A, Bayne RA, Hagen CP, Mitchell RT, Anderson RA, Sharpe RM.

Sci Rep. 2016 Jan 27;6:19789. doi: 10.1038/srep19789.

7.

The impact of obesity on male fertility.

Chambers TJ, Richard RA.

Hormones (Athens). 2015 Oct-Dec;14(4):563-8. doi: 10.14310/horm.2002.1621. Review.

8.

Fetal programming of adult Leydig cell function by androgenic effects on stem/progenitor cells.

Kilcoyne KR, Smith LB, Atanassova N, Macpherson S, McKinnell C, van den Driesche S, Jobling MS, Chambers TJ, De Gendt K, Verhoeven G, O'Hara L, Platts S, Renato de Franca L, Lara NL, Anderson RA, Sharpe RM.

Proc Natl Acad Sci U S A. 2014 May 6;111(18):E1924-32. doi: 10.1073/pnas.1320735111. Epub 2014 Apr 21.

9.

Are cathepsin k inhibitors just another class of anti-resorptives?

Chambers TJ, Tobias JH.

J Clin Endocrinol Metab. 2013 Nov;98(11):4329-31. doi: 10.1210/jc.2013-2630. Epub 2013 Sep 20. No abstract available.

PMID:
24057285
10.

Wnt signalling in pituitary development and tumorigenesis.

Chambers TJ, Giles A, Brabant G, Davis JR.

Endocr Relat Cancer. 2013 May 20;20(3):R101-11. doi: 10.1530/ERC-13-0005. Print 2013 Jun. Review.

PMID:
23689382
11.

Distinctive subdomains in the resorbing surface of osteoclasts.

Szewczyk KA, Fuller K, Chambers TJ.

PLoS One. 2013;8(3):e60285. doi: 10.1371/journal.pone.0060285. Epub 2013 Mar 21.

12.

How are osteoclasts induced to resorb bone?

Chambers TJ, Fuller K.

Ann N Y Acad Sci. 2011 Dec;1240:1-6. doi: 10.1111/j.1749-6632.2011.06249.x. Review.

PMID:
22172032
13.

Urocortin is a novel regulator of osteoclast differentiation and function through inhibition of a canonical transient receptor potential 1-like cation channel.

Combs CE, Fuller K, Kumar H, Albert AP, Pirianov G, McCormick J, Locke IC, Chambers TJ, Lawrence KM.

J Endocrinol. 2012 Feb;212(2):187-97. doi: 10.1530/JOE-11-0254. Epub 2011 Nov 14.

PMID:
22083217
14.

Bone is not essential for osteoclast activation.

Fuller K, Ross JL, Szewczyk KA, Moss R, Chambers TJ.

PLoS One. 2010 Sep 17;5(9). pii: e12837. doi: 10.1371/journal.pone.0012837.

15.

The birth of the osteoclast.

Chambers TJ.

Ann N Y Acad Sci. 2010 Mar;1192:19-26. doi: 10.1111/j.1749-6632.2009.05224.x. Review.

PMID:
20392213
16.

The resorptive apparatus of osteoclasts supports lysosomotropism and increases potency of basic versus non-basic inhibitors of cathepsin K.

Fuller K, Lindstrom E, Edlund M, Henderson I, Grabowska U, Szewczyk KA, Moss R, Samuelsson B, Chambers TJ.

Bone. 2010 May;46(5):1400-7. doi: 10.1016/j.bone.2010.01.374. Epub 2010 Jan 25.

PMID:
20097319
17.

Neuroadapted yellow fever virus strain 17D: a charged locus in domain III of the E protein governs heparin binding activity and neuroinvasiveness in the SCID mouse model.

Nickells J, Cannella M, Droll DA, Liang Y, Wold WS, Chambers TJ.

J Virol. 2008 Dec;82(24):12510-9. doi: 10.1128/JVI.00458-08. Epub 2008 Oct 8.

18.

West Nile 25A virus infection of B-cell-deficient ((micro)MT) mice: characterization of neuroinvasiveness and pseudoreversion of the viral envelope protein.

Chambers TJ, Droll DA, Walton AH, Schwartz J, Wold WS, Nickells J.

J Gen Virol. 2008 Mar;89(Pt 3):627-35. doi: 10.1099/vir.0.83297-0.

PMID:
18272752
19.

Cathepsin K inhibitors prevent matrix-derived growth factor degradation by human osteoclasts.

Fuller K, Lawrence KM, Ross JL, Grabowska UB, Shiroo M, Samuelsson B, Chambers TJ.

Bone. 2008 Jan;42(1):200-11. Epub 2007 Sep 26.

PMID:
17962093
20.

JE Nakayama/JE SA14-14-2 virus structural region intertypic viruses: biological properties in the mouse model of neuroinvasive disease.

Chambers TJ, Droll DA, Jiang X, Wold WS, Nickells JA.

Virology. 2007 Sep 15;366(1):51-61. Epub 2007 May 22.

21.

Regulation and enzymatic basis of bone resorption by human osteoclasts.

Fuller K, Kirstein B, Chambers TJ.

Clin Sci (Lond). 2007 Jun;112(11):567-75.

PMID:
17241109
22.

A novel assay for analysis of the regulation of the function of human osteoclasts.

Kirstein B, Grabowska U, Samuelsson B, Shiroo M, Chambers TJ, Fuller K.

J Transl Med. 2006 Nov 7;4:45.

23.

Chimeric Japanese encephalitis virus/dengue 2 virus infectious clone: biological properties, immunogenicity and protection against dengue encephalitis in mice.

Chambers TJ, Jiang X, Droll DA, Liang Y, Wold WS, Nickells J.

J Gen Virol. 2006 Nov;87(Pt 11):3131-40.

PMID:
17030845
24.

Secretion of tartrate-resistant acid phosphatase by osteoclasts correlates with resorptive behavior.

Kirstein B, Chambers TJ, Fuller K.

J Cell Biochem. 2006 Aug 1;98(5):1085-94.

PMID:
16475168
25.

Murine osteoclast formation and function: differential regulation by humoral agents.

Fuller K, Kirstein B, Chambers TJ.

Endocrinology. 2006 Apr;147(4):1979-85. Epub 2005 Dec 29.

PMID:
16384864
26.

Inhibition of colony-stimulating-factor-1 signaling in vivo with the orally bioavailable cFMS kinase inhibitor GW2580.

Conway JG, McDonald B, Parham J, Keith B, Rusnak DW, Shaw E, Jansen M, Lin P, Payne A, Crosby RM, Johnson JH, Frick L, Lin MH, Depee S, Tadepalli S, Votta B, James I, Fuller K, Chambers TJ, Kull FC, Chamberlain SD, Hutchins JT.

Proc Natl Acad Sci U S A. 2005 Nov 1;102(44):16078-83. Epub 2005 Oct 25.

27.

Recent developments in cathepsin K inhibitor design.

Grabowskal U, Chambers TJ, Shiroo M.

Curr Opin Drug Discov Devel. 2005 Sep;8(5):619-30. Review.

PMID:
16159024
28.

The effect of oestrogen on megakaryocyte differentiation and platelet counts in vivo.

Fox SW, Chambers TJ.

Int J Cardiol. 2006 May 24;109(3):359-66. Epub 2005 Aug 9.

PMID:
16084610
29.

Plasma chemokine levels correlate with the outcome of antiviral therapy in patients with hepatitis C.

Butera D, Marukian S, Iwamaye AE, Hembrador E, Chambers TJ, Di Bisceglie AM, Charles ED, Talal AH, Jacobson IM, Rice CM, Dustin LB.

Blood. 2005 Aug 15;106(4):1175-82. Epub 2005 Apr 28.

30.

Yellow fever virus NS2B-NS3 protease: characterization of charged-to-alanine mutant and revertant viruses and analysis of polyprotein-cleavage activities.

Chambers TJ, Droll DA, Tang Y, Liang Y, Ganesh VK, Murthy KH, Nickells M.

J Gen Virol. 2005 May;86(Pt 5):1403-13.

PMID:
15831952
31.

Recombination and flavivirus vaccines: a commentary.

Monath TP, Kanesa-Thasan N, Guirakhoo F, Pugachev K, Almond J, Lang J, Quentin-Millet MJ, Barrett AD, Brinton MA, Cetron MS, Barwick RS, Chambers TJ, Halstead SB, Roehrig JT, Kinney RM, Rico-Hesse R, Strauss JH.

Vaccine. 2005 Apr 27;23(23):2956-8. No abstract available.

PMID:
15811640
32.

Quasispecies heterogeneity within the E1/E2 region as a pretreatment variable during pegylated interferon therapy of chronic hepatitis C virus infection.

Chambers TJ, Fan X, Droll DA, Hembrador E, Slater T, Nickells MW, Dustin LB, Dibisceglie AM.

J Virol. 2005 Mar;79(5):3071-83.

33.
34.

Hydrogen peroxide is essential for estrogen-deficiency bone loss and osteoclast formation.

Lean JM, Jagger CJ, Kirstein B, Fuller K, Chambers TJ.

Endocrinology. 2005 Feb;146(2):728-35. Epub 2004 Nov 4.

PMID:
15528306
35.

Tumor necrosis factor-alpha mediates osteopenia caused by depletion of antioxidants.

Jagger CJ, Lean JM, Davies JT, Chambers TJ.

Endocrinology. 2005 Jan;146(1):113-8. Epub 2004 Sep 23.

PMID:
15388652
36.
37.

Parathyroid hormone activates adhesion in bone marrow stromal precursor cells.

Davies J, Chambers TJ.

J Endocrinol. 2004 Mar;180(3):505-13.

PMID:
15012605
38.

HCV E2 glycoprotein: mutagenesis of N-linked glycosylation sites and its effects on E2 expression and processing.

Slater-Handshy T, Droll DA, Fan X, Di Bisceglie AM, Chambers TJ.

Virology. 2004 Feb 5;319(1):36-48.

39.

Mitf-PU.1 interactions with the tartrate-resistant acid phosphatase gene promoter during osteoclast differentiation.

Partington GA, Fuller K, Chambers TJ, Pondel M.

Bone. 2004 Feb;34(2):237-45.

PMID:
14962802
40.

Pathogenesis of flavivirus encephalitis.

Chambers TJ, Diamond MS.

Adv Virus Res. 2003;60:273-342. Review. No abstract available.

PMID:
14689697
41.

Preface to volume 60 the flaviviruses: pathogenesis and immunity.

Chambers TJ, Monath TP.

Adv Virus Res. 2003;60:xiii-xiv. No abstract available.

PMID:
14689689
42.

Preface to the flaviviruses.

Chambers TJ, Monath TP.

Adv Virus Res. 2003;60:ix-xi. No abstract available.

PMID:
14689688
43.
44.

TGF-beta-induced SOCS3 expression augments TNF-alpha-induced osteoclast formation.

Lovibond AC, Haque SJ, Chambers TJ, Fox SW.

Biochem Biophys Res Commun. 2003 Oct 3;309(4):762-7.

PMID:
13679037
45.

A crucial role for thiol antioxidants in estrogen-deficiency bone loss.

Lean JM, Davies JT, Fuller K, Jagger CJ, Kirstein B, Partington GA, Urry ZL, Chambers TJ.

J Clin Invest. 2003 Sep;112(6):915-23.

46.
47.

Accumulation of B lymphocytes with a naive, resting phenotype in a subset of hepatitis C patients.

Ni J, Hembrador E, Di Bisceglie AM, Jacobson IM, Talal AH, Butera D, Rice CM, Chambers TJ, Dustin LB.

J Immunol. 2003 Mar 15;170(6):3429-39.

48.
49.

CCL9/MIP-1gamma and its receptor CCR1 are the major chemokine ligand/receptor species expressed by osteoclasts.

Lean JM, Murphy C, Fuller K, Chambers TJ.

J Cell Biochem. 2002;87(4):386-93.

PMID:
12397598

Supplemental Content

Loading ...
Support Center